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Methamphetamine is a highly addictive drug that acts as a stimulant for the central nervous system. 
It increases alertness and physical activity but can cause cardiac dysrhythmias, hypertension, 
hallucinations and violent behavior. The excretion rate of methamphetamine by the kidney can be 
seriously altered by urinary pH. Methamphetamine is a weak base, consequently, the proportion 
of the excreted amount of unchanged drug can vary from as little as 2% in alkaline (pH ≥8.0) to 
76% in acidic urine (pH ≤5.0). Methamphetamine is metabolized by hepatic metabolism and renal 
excretion via cytochrome P450 2D6 (CYP2D6). The effects of methamphetamine on the kidneys 
can be divided into the following sub-groups: vascular effects, non-traumatic rhabdomyolysis and 
direct nephrotoxicity. Additionally, methamphetamine directly stimulates the release of ET-1, a 
potent vasoconstrictor. ET-1 stimulates vasoconstriction, inflammation and fibrosis in kidney, thus 
promoting hypertension, atherosclerosis and chronic kidney disease.
ABSTRACT
Implication for health policy/practice/research/medical education:
The effects of methamphetamine on kidneys could be divided into three sub-groups: vascular effects, non-traumatic rhabdomyolysis, and 
direct nephrotoxicity. Methamphetamine directly stimulates the release of endothelin 1 (ET-1) leading to vasoconstriction, inflammation 
and fibrosis, thus inducing hypertension, arterial sclerosis and chronic kidney disease. Acute kidney injury is also seen frequently with 
methamphetamine and is triggered indirectly via vascular (pre-renal) effects and rhabdomyolysis.
Please cite this paper as: Godrati S, Pezeshgi A, Valizadeh R, James Kellner S, Radfar SR. Acute and delayed nephropathy due to 
methamphetamine abuse. J Nephropathol. 2020;9(3):e22. DOI: 10.34172/jnp.2020.22.
Introduction
Methamphetamine, a methylated analogue of amphetamine 
that is more lipid soluble and more difficult to metabolize, 
has been applied to remedy attention deficit hyperactivity 
illness. Methamphetamine is a potent addictive 
psycho-stimulant causing insomnia and euphoria (1). 
Methamphetamine can be used by oral administration, 
intravenous injection and snorting, inhalation or smoking 
of the methamphetamine hydrochloride salt.
Materials and Methods
For this review, we used various sources including 
PubMed, directory of open access journals (DOAJ), 
Embase, Web of Science, Google Scholar and Scopus. The 
search was conducted with the following keywords or their 
equals; methamphetamine, rhabdomyolysis, endothelin, 
vasoconstrictor, acute kidney injury, chronic kidney 
disease, nephrotoxicity, inflammation, hypertension, 
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Methamphetamine in urine 
The excretion rate of methamphetamine by the kidney can 
seriously alter according to urinary pH. Methamphetamine 
is a weak base and the proportion of unchanged 
methamphetamine excreted can alter from as little as 2% 
in alkaline (pH ≥8.0) to 76% in acidic urine (pH ≤5.0). 
Acidic urine enhances methamphetamine excretion and 
reduces its half-life in the body, while alkaline urine 
diminishes excretion and lengthens survival time in the 
body. Methamphetamine is distributed throughout the 
whole body. The re-absorption of methamphetamine in 
human is highest in the kidneys. The high accumulation 
of methamphetamine in kidneys could explain its high 
urine excretion rate (2,3).
Metabolism of methamphetamine
Methamphetamine is metabolized by hepatic metabolism 
and renal excretion (Figure 1) via aromatic hydroxylation of 
methamphetamine by Cytochrome P450 2D6 (CYP2D6), 
producing primarily 4-hydroxymethamphetamine or 
N-demethylation of methamphetamine to produce 
amphetamine, catalyzed by CYP2D6; followed by beta-
hydroxylation of amphetamine to create nor-ephedrine 
(4,5).
Methamphetamine and renal function and structure
The kidneys are responsible for filtering toxins from the 
body and excreting through the urine. In fact, the majority 
of illicit substances are excreted through the kidneys. 
Acute kidney injury is rare damage to the kidneys that 
causes them to not work correctly. It varies from minor 
loss of kidney function to complete kidney failure. The 
causes of acute kidney injury are commonly categorized 
into pre-renal, intrinsic and post-renal (7-9). Chronic 
kidney disease is usually caused by long-term diseases, 
such as hypertension or diabetes. Long-term use of illicit 
drugs could also cause gradual damage to kidneys and 
decrease their function over time. 
Methamphetamine is one of the substances that is 
Figure 1. Main methamphetamine metabolite pathway by CYP2D6 
(6).
widely abused. This can disrupt the normal function 
of cellular and molecular systems. Several events such 
as oxidative stress, aging, apoptosis, necrosis and 
reactive oxygen species (ROS) are thought to play a 
role after administration of methamphetamine (7-10). 
Methamphetamine intoxication could be diagnosed 
using immunohistochemical changes in the kidney and 
renal function. The 70 kDa heat shock protein (HSP70), 
8-hydroxy-20-deoxyguanosine (8-OHdG), 4-hydroxy-
2-nonenal (4-HNE), and Cu/Zn superoxide dismutase 
(SOD) (8,9), malondialdehyde (MDA), catalase (CAT) 
activity, glutathione (GSH) and glutathione peroxidase 
(GPx) levels  are oxidative injury related biomarkers 
in the kidney of methamphetamine abusers (10). The 
measurement of myoglobin is used to diagnose muscle 
injury. Additionally, tumor necrosis factor (TNF) is a pro-
inflammatory cytokine and is released from the kidney in 
response to ischemia and reperfusion (7-10). 
Despite the fact that oxidative stress in kidneys is more 
severe than in brain and other organs (10), there are many 
reports about neurologic effects of methamphetamine, 
whereas the effects of methamphetamine on the kidney 
have not been paid enough attention. 
The effects of 3,4-methylenedioxy-methamphetamine 
(MDMA) on the kidney cells are investigated by different 
research groups (11-13). In this review, the impact of 
chronic and acute methamphetamine abuse on kidney 
is the main objective. There are several reports regarding 
renal effects of this substance including renal function 
impairment and renal necrotizing vasculitis (14). Also 
there are reports suggesting serum creatinine level increase 
in renal transplant receivers, one year after transplantation 
from addicted donors (15). Additionally, effects of 
methamphetamine on histopathology parameters of kidney 
had been described (16). The effects of methamphetamine 
on kidneys can be classified into the following sub-groups: 
vascular effects, non-traumatic rhabdomyolysis and direct 
nephrotoxicity. These categories are discussed in further 
details below.
Vascular effects of methamphetamine
In a-5-year study of patient’s medical history who 
administered methamphetamine, analysis of kidney 
biopsy samples revealed severe necrotizing vasculitis of 
arterioles and glomeruli (17). It is generally accepted that 
methamphetamine has potent vasoconstrictive effects, 
but its exact mechanism at the cellular level has not 
been known. Accordingly, an investigation found how 
methamphetamine directly stimulates the liberation of 
ET-1, as the most potent renal vasoconstrictor known 
(100-times more potent than noradrenaline), proposing 
an additional mechanism which methamphetamine 
induces vasoconstriction (18). ET-1production by 
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the kidney is much higher than any other organ (19). 
Increased production of endothelin1causes decreased 
renal blood flow and glomerular filtration rate (GFR) and 
consequently induces renal hypertension (20). In diabetic 
and hypertensive patients, plasma ET-1 concentrations 
can be increased several times compared to normal 
healthy individuals (21,22). The participation of ET-1 
in renal function has been extensively studied (23). Two 
key renal actions have been recognized from these studies; 
(i) the adjustment of renal hemodynamics associated 
with its vascular activity and (ii) the variation of water 
and sodium secretion through its action on tubular cells. 
Hemodynamic changes induced by endothelin1causes 
a decrease in urine flow and sodium secretion. Regional 
production of endothelin1in tubular cells is adjusted by 
the osmolar condition and thus produces reverse effects 
leading to diuresis and natriuresis (hypernatremia). Many 
researchers have focused on the effects of ET-1 on the 
kidneys. But so far, there has been no study of the adverse 
effects of METH –induce renal insufficiency with ET-1. 
Vasoconstriction induced by methamphetamine results in 
major life-threatening complications as discussed below.
Hypertension as the side effect of methamphetamine
Methamphetamine indirectly increases blood pressure by 
constriction of blood vessels. It is important to identify 
that METH-induced hypertension is because of a hyper-
adrenergic state (24,25). This hyper-adrenergic state 
triggers both α-adrenoceptors (mediating peripheral 
vasoconstriction) and β2-adrenoreceptors (mediating 
peripheral vasodilation). Additionally, ET-1 prompts 
the creation of angiotensin II (vasoconstrictor) through 
escalating the activity of angiotensin-converting enzyme 
(26,27), a main factor of hypertension.
Hypertension is a prevalent co-morbidity associated 
with chronic kidney disease. Hypertension is an 
important cause of chronic kidney disease too and plays 
a significant role in its progression. Also, hypertension is 
highly prevalent in chronic kidney disease patients, which, 
if uncontrolled, results in high risk of cardiovascular 
injury and death. Methamphetamine abuse can cause 
hypertension which is followed by chronic kidney disease. 
Ischemia and hypoxia induced by methamphetamine
Vascular ischemia includes disruption of the arterial 
blood flow to tissue. Amphetamines have vasoconstrictive 
properties that force the kidneys to ischemia or hypoxia 
(28). ET-1is assumed to contribute to the pathogenesis 
of ischemia-reperfusion induced acute kidney injury 
(24). Intestinal ischemia or diminished blood flow to the 
small bowels can also be a result of methamphetamine 
administration. Amphetamine and methamphetamine 
can prompt progressive necrotizing vasculitis in different 
organs, including renal and gastrointestinal systems. There 
are few case reports of intestinal ischemia or infarction 
associated with methamphetamine abuse, which is 
suggested to be caused mainly by vasoconstriction and 
vasculitis (29,30). Hemodynamic instability may result 
in pre-renal acute kidney injury due to blood volume 
deficiency (hypovolemia) and, if continued and severe, 
can result in ischemic acute kidney injury (20,31).
Hyperthermia caused by methamphetamine
Hyperthermia by methamphetamine can produce 
indirect adverse effects on kidney due to damage to 
renal vasculature (32). Methamphetamine limits heat 
distribution to the external environment and potentiates 
body hyperthermia especially when injected intravenously. 
Hyperthermia enhances methamphetamine toxicity 
directly through disorder of protein function, ion channels 
and enhanced ROS production. Hyperthermia can lead 
to rhabdomyolysis, the breakdown of muscle tissue, 
hypotension, disseminated intravascular coagulation, and 
acute kidney injury.
Dysnatremia
A variety of factors contribute to the development of 
dysnatremia. Hypernatremia and hyponatremia both 
occur. The two main factors are dehydration and the 
syndrome of inappropriate antidiuretic hormone secretion 
SIADH, which is prompted by methamphetamine 
metabolites. Methamphetamine abusers usually do not 
drink sufficient amounts of fluids, causing dehydration. 
Methamphetamine metabolites are known to increase the 
synaptic concentration of serotonin and dopamine, both 
of which are involved in the release of arginine induced 
vasopressin (33). 
Non-traumatic rhabdomyolysis
Amphetamines are myotoxic and lead to rhabdomyolysis 
causing impediment of the vasculature and tubular 
deterioration as a result of the deposition of myoglobin 
(9,34). Released myoglobin damages and reduces the 
function of filtration in kidneys resulting in acute kidney 
injury or renal failure. Methamphetamine was implicated 
as the most prevalent cause of rhabdomyolysis in several 
reports (35-37). During myocyte damage, the level of 
free myoglobin in the plasma increases and is filtered 
by the kidneys. Myoglobinemia and myoglobinuria 
have been linked to the progress of acute kidney injury. 
Rhabdomyolysis induced-acute kidney injury occurs 
in 13% to 50% of all cases. The pathophysiology of 
rhabdomyolysis-induced acute kidney injury is thought 
to be triggered by myoglobin as the toxin causing renal 
failure. The major mechanisms in which myoglobin 
causes renal failure are renal vasoconstriction and tubular 
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obstruction leading to lipid peroxidation and tubular 
damage. Recently, most reports state free iron-mediated 
formation of hydroxyl radicals (Fenton reactions) as the 
pathway starting lipid peroxidation. Alkaline conditions 
prevent myoglobin-induced lipid peroxidation by 
stabilizing the reactive ferryl myoglobin complex (38). 
In the acidic environment and hypovolemia, myoglobin 
reacts with Tamm-Horsfall protein and precipitates into 
tubules, which may then impede tubular flow (post-renal 
obstruction at tubular level). 
Also, secretion of myoglobin causes increase 
concentrations of plasma ET-1. It is concluded that ET-
1is at least partially, contributing to the significant tubular 
cell injury detected in myoglobinuric nephropathy (39).
Direct nephrotoxicity
While the effect of methamphetamine exposure on 
the transplanted kidney is not identified, there is rising 
confirmation in support of short and long-term renal 
dysfunction with acute or prolonged methamphetamine 
use. Clearly, it seems likely that donor kidneys from 
methamphetamine users are compromised and lead to 
reduced renal function in the transplant (18). In the 
situation of severe acute intoxication, methamphetamine 
exposure can provoke acute kidney injury with later 
improvement or cause chronic kidney disease needing 
dialysis. The effect of chronic methamphetamine exposure 
is, however, less established. 
Intravenous amphetamine and methamphetamine use 
is known to cause acute kidney injury rarely due to acute 
interstitial nephritis (AIN) in the absence of any vascular 
or glomerular damage. In the studies by Foley et al (40) 
and Raju et al (41), direct effects of the amphetamine 
and methamphetamine are causes of AIN with negative 
test for myoglobin (the absence of muscle damage and 
any glomerular or vascular injury). Additionally, from 
renal biopsies performed in Cape Town patients who 
had been abusing with methamphetamine, almost 60% 
showed mesangiocapillary glomerulonephritis type 1. 
However, it is not known how methamphetamine causes 
lesions resembling mesangiocapillary glomerulonephritis 
(42). Conventional in-vivo evidence suggests that 
ET-1 functions as a mitogen in mesangiocapillary 
glomerulonephritis. The kidney is more sensitive to 
exogenous ET-1 as compared to all other organs. ET-1 
stimulates vasoconstriction, inflammation and fibrosis, 
thereby promoting hypertension, atherosclerosis and 
chronic kidney disease. Increased urinary ET-1 secretion 
is related to a higher degree of renal failure and glomerular 
sclerosis (43,44). Furthermore, recent investigations show 
that administration of the ET-1antagonist reduced renal 
tissue damages and lead to improved kidney function 
(45,46). Similarly, N-acetylcysteine amide and caffeic 
acid are as recognized therapeutic drugs to protect tissue 
against METH-induced toxicity (12,13).
Conclusion
The effects of methamphetamine on the kidneys can 
be divided into three sub-groups: vascular effects, non-
traumatic rhabdomyolysis and direct nephrotoxicity. 
Additionally, investigations have demonstrated that 
methamphetamine directly stimulates the release of 
ET-1. ET-1 stimulates vasoconstriction, inflammation 
and fibrosis, thus inducing hypertension, arterial 
sclerosis and chronic kidney disease. Frequently, effect 
of methamphetamine on kidney is indirect via vascular 
(pre-renal) effects and rhabdomyolysis. Direct effect of 
the methamphetamine on kidney (AIN) is rarely reported. 
Donor kidneys from methamphetamine abusers should 
be carefully assessed before transplanting.
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